Mission GBM

Home
Archive
About
Breaking News: FDA Approves Tovorafenib (Ojemda®) for Pediatric LGG with BRAF Mutations
A Wonderful Day for pLGG patients and their families
 • 
Scott L. Rakestraw, PhD
MissionGBM FAQs - Part 2
Because you have lots of questions
 • 
Scott L. Rakestraw, PhD
MissionGBM FAQs - Part 1
You ask; We answer
 • 
Scott L. Rakestraw, PhD
AACR Brain Cancer Highlights
A tantalizing Phase 1 study of AZD-1390, some potential insights into poor CAR-T efficacy against solid tumors, and disappointing OS performance of…
 • 
Scott L. Rakestraw, PhD
The Reality of Clinical Trials
Often a frustrating slog through inaccurate information and hidden conflicts of interest
 • 
Scott L. Rakestraw, PhD
Quackfoolery
In God We Trust. Everyone else must bring #Data
 • 
Scott L. Rakestraw, PhD

March 2024

Marizomib Fails a Phase 3 Clinical Trial in ndGBM Patients
Big Study. Muddy Biology. Ugh!
 • 
Scott L. Rakestraw, PhD
Novocure Reports METIS Top Line Clinical Trial Results for Brain Metastases from NSCLC
Promising, but we will wait for the full data presentation
 • 
Scott L. Rakestraw, PhD
Julie Update: Here Be the Dragons
All oncology treatments have Adverse Events (AEs). Sometimes, the AEs are worse than the cancer.
 • 
Scott L. Rakestraw, PhD
0:43
CAR-Ts and GBM: A Long Way Yet to Go
Are you ready for a N-valent CAR-T (N>4) with concomitant checkpoint inhibition…and the (S)AEs that come with it…to be available in perhaps 10 years?
 • 
Scott L. Rakestraw, PhD

February 2024

FDA and EMA Accept Vorasidenib Regulatory Submissions for the Treatment of IDH-mutant Diffuse Glioma
News of Enormous Potential for IDH-mutant Glioma Patients Within the past 24 hours, Servier reported that it has submitted both a New Drug Application…
 • 
Scott L. Rakestraw, PhD
Investing in Brain Cancer – Part 5
Models Designed to Bridge to Institutional & Strategic Investors
 • 
Scott L. Rakestraw, PhD
© 2024 Scott L. Rakestraw, PhD
Privacy ∙ Terms ∙ Collection notice
Start WritingGet the app
Substack is the home for great culture